Radisens Diagnostics
Cork
About Radisens Diagnostics
The potential value of Point-of-Care Testing (PoCT) is well-established; especially in the US. However, the tests currently in use typically measure individual analytes with a wide diversity of instruments that are poorly connected with patient’s health records, providing frustration and inefficiencies for Health Care. With the increasing chronic disease epidemic (diabetes, heart disease, hypertension, kidney disease,), diagnostics at the bedside and in the physician's office are needed to close the linkage between diagnostics and therapies. However, no device offers a test menu that maps the complete chronic and acute disease pathways needed by physicians for informed diagnosis and monitoring. Radisens Diagnostics is developing a digital diagnostic device to perform routine chronic and acute tests needed at point-of-care in GP clinics, emergency rooms and outpatient departments. With initial chronic disease panels of diabetes + heart disease and hypertension + chronic kidney, the company’s roadmap includes panels for cell counting, cardiac and oncology targets. Its disruptive device platform integrates immunochemistry, clinical chemistry and haematology assays onto multiplexed test panels requiring only a drop of blood giving instant results. Its vision of placing diagnostic devices into every physician office and acute hospital setting for chronic / acute conditions will drive significant cost savings and enable performance based incentives required by insurers.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.5M
- Last round: Grant (Jul 2015)
- Website: radisens.com
- Phone: +353 212339140
Industries & Categories
Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/radisens-diagnostics-3390623 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.